Swedish pharmaceutical company Medivir will acquire BioPhausia, another Sweden-based firm, in a deal that will "create a platform" for its hepatitis C treatment, according to Pharma Times.

Medivir is offering a combination of cash and new shares, putting BioPhausia’s value at about $90 million.

Medvir says that BioPhausia will provide it with "complementary competencies in regulatory affairs, logistics, distribution, marketing, sales and quality assurance," plus a presence across a part of the Nordic region.